title: Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report.
abstract: BACKGROUND
  A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing.
  
  
  METHODS
  A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up.
  
  
  CONCLUSIONS
  GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, IRCCS-Arcispedale S. Maria Nuova of Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy. nucerags@gmail.com
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Nucera
authors.forename: Vincenzo Dario
authors.initials: VD
authors.lastname: Mandato
authors.forename: Maria Carolina
authors.initials: MC
authors.lastname: Gelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Palomba
authors.forename: Giovanni Battista
authors.initials: GB
authors.lastname: La Sala
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D005260:Female; D059247:Fertility Preservation; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000819:agonists* / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D007436:Intrauterine Devices, Medicated; D016729:Leuprolide / Q000009:adverse effects / Q000627:therapeutic use; D016912:Levonorgestrel / Q000008:administration & dosage*; D009367:Neoplasm Staging; D011247:Pregnancy; D012074:Remission Induction; D047929:Term Birth
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone; D016912:Levonorgestrel; D016729:Leuprolide